-
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis, Rochester, Saint Paul
-
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
NCT07728383 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285 ·
Phase: Phase 3 ·
Ages: 8 Years to 18 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis, Richfield
-
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis, Richfield
-
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 ·
Phase: Phase 3 ·
Ages: 18 Years to 79 Years ·
Sex: All (male and female)
· Minnesota: Mankato, Minneapolis
-
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Maplewood
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Mankato
-
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464 ·
Phase: Phase 3 ·
Ages: 6 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546 ·
Phase: Phase 3 ·
Ages: 4 Years and older ·
Sex: All (male and female)
· Minnesota: Saint Paul
-
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07533175 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Breastmilk in Response to a Bout of Exercise
NCT06892483 ·
Phase: Not specified ·
Ages: 18 Years to 45 Years ·
Sex: Female
· Minnesota: Rochester
-
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519 ·
Phase: Phase 2 ·
Ages: 7 Years to 25 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Circadian Rhythms in Human Adipose
NCT06891534 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361 ·
Phase: Phase 3 ·
Ages: 18 Years to 79 Years ·
Sex: All (male and female)
· Minnesota: Mankato, Richfield
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433 ·
Phase: Phase 3 ·
Ages: 45 Years to 99 Years ·
Sex: All (male and female)
· Minnesota: Maplewood, Minneapolis
-
Exercise Response in Humans With Obesity
NCT05857150 ·
Phase: Not specified ·
Ages: 20 Years to 45 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Family, Responsibility, Education, Support, and Health for Food Responsiveness
NCT06207110 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 7 Years to 12 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Fibrosis Lessens After Metabolic Surgery
NCT06374875 ·
Phase: Phase 4 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
NCT06390345 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
NCT07213466 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Insulin Regulation of Lipolysis and Lipolysis Proteins
NCT03866408 ·
Phase: Early Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
NCT03868592 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Minnesota: Mankato, Maplewood, Minneapolis
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
NCT06770049 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Project SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults
NCT06226077 ·
Phase: Phase 1, Phase 2 ·
Ages: 21 Years to 75 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
NCT04228978 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Minneapolis
-
Regional Lipolysis Insulin Regulation
NCT06392854 ·
Phase: Early Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
NCT06416969 ·
Phase: Early Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
The Weight of Cardiovascular Disease
NCT06053645 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Minnesota: Rochester
-
Tirzepatide in PWS, HO and GNSO
NCT06901245 ·
Phase: Phase 4 ·
Ages: 18 Years to 26 Years ·
Sex: All (male and female)
· Minnesota: Saint Paul
-
Upper Body Subcutaneous Exosome Release in Response to a Meal in Obesity
NCT07031297 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
Weight Loss Through Mayo Clinic Diet
NCT06862375 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· Minnesota: Rochester
-
tDCS With Cognitive Training to Reduce Impulsivity and Weight in Veterans With Obesity
NCT05225233 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Minnesota: Minneapolis